A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency

Kazuaki Taguchi; Toshikazu Miyakawa; Takafumi Ohmura; Momoko Horio; Yoshihisa Anraku; Tatsuya Okada; Hiroshi Mizuta; Hideyuki Saito; Tatsuya Kawaguchi

doi:10.3109/00365548.2012.708783

A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency

Kazuaki Taguchi, Toshikazu Miyakawa, Takafumi Ohmura, Momoko Horio, Yoshihisa Anraku, Tatsuya Okada, Hiroshi Mizuta, Hideyuki Saito, Tatsuya Kawaguchi

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

The optimal dosage of linezolid to avoid hematologic toxicity is unknown. We report the case of an 87-y-old woman with renal insufficiency who developed a surgical site infection with refractory methicillin-resistant Staphylococcus aureus. The standard dosage of linezolid (1200 mg daily) was not initially tolerated by the patient due to severe thrombocytopenia, but she was successfully treated when the dose was reduced by half (600 mg daily) based on a population pharmacokinetic-pharmacodynamic model. Appropriate dose adjustments can be made to optimize linezolid therapy especially in cases with preexisting renal dysfunction.

Original language	English
Pages (from-to)	77-80
Number of pages	4
Journal	Scandinavian Journal of Infectious Diseases
Volume	45
Issue number	1
DOIs	https://doi.org/10.3109/00365548.2012.708783
Publication status	Published - 2013 Jan
Externally published	Yes

Keywords

Linezolid
Renal insufficiency
Thrombocytopenia

ASJC Scopus subject areas

Immunology and Microbiology(all)
Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/00365548.2012.708783

Cite this

Taguchi, K., Miyakawa, T., Ohmura, T., Horio, M., Anraku, Y., Okada, T., Mizuta, H., Saito, H., & Kawaguchi, T. (2013). A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency. Scandinavian Journal of Infectious Diseases, 45(1), 77-80. https://doi.org/10.3109/00365548.2012.708783

A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency. / Taguchi, Kazuaki; Miyakawa, Toshikazu; Ohmura, Takafumi et al.
In: Scandinavian Journal of Infectious Diseases, Vol. 45, No. 1, 01.2013, p. 77-80.

Research output: Contribution to journal › Article › peer-review

Taguchi, K, Miyakawa, T, Ohmura, T, Horio, M, Anraku, Y, Okada, T, Mizuta, H, Saito, H & Kawaguchi, T 2013, 'A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency', Scandinavian Journal of Infectious Diseases, vol. 45, no. 1, pp. 77-80. https://doi.org/10.3109/00365548.2012.708783

@article{01ea8767e4eb47c8a5db72fb28aba551,

title = "A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency",

abstract = "The optimal dosage of linezolid to avoid hematologic toxicity is unknown. We report the case of an 87-y-old woman with renal insufficiency who developed a surgical site infection with refractory methicillin-resistant Staphylococcus aureus. The standard dosage of linezolid (1200 mg daily) was not initially tolerated by the patient due to severe thrombocytopenia, but she was successfully treated when the dose was reduced by half (600 mg daily) based on a population pharmacokinetic-pharmacodynamic model. Appropriate dose adjustments can be made to optimize linezolid therapy especially in cases with preexisting renal dysfunction.",

keywords = "Linezolid, Renal insufficiency, Thrombocytopenia",

author = "Kazuaki Taguchi and Toshikazu Miyakawa and Takafumi Ohmura and Momoko Horio and Yoshihisa Anraku and Tatsuya Okada and Hiroshi Mizuta and Hideyuki Saito and Tatsuya Kawaguchi",

year = "2013",

month = jan,

doi = "10.3109/00365548.2012.708783",

language = "English",

volume = "45",

pages = "77--80",

journal = "Infectious Diseases",

issn = "2374-4235",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency

AU - Taguchi, Kazuaki

AU - Miyakawa, Toshikazu

AU - Ohmura, Takafumi

AU - Horio, Momoko

AU - Anraku, Yoshihisa

AU - Okada, Tatsuya

AU - Mizuta, Hiroshi

AU - Saito, Hideyuki

AU - Kawaguchi, Tatsuya

PY - 2013/1

Y1 - 2013/1

N2 - The optimal dosage of linezolid to avoid hematologic toxicity is unknown. We report the case of an 87-y-old woman with renal insufficiency who developed a surgical site infection with refractory methicillin-resistant Staphylococcus aureus. The standard dosage of linezolid (1200 mg daily) was not initially tolerated by the patient due to severe thrombocytopenia, but she was successfully treated when the dose was reduced by half (600 mg daily) based on a population pharmacokinetic-pharmacodynamic model. Appropriate dose adjustments can be made to optimize linezolid therapy especially in cases with preexisting renal dysfunction.

AB - The optimal dosage of linezolid to avoid hematologic toxicity is unknown. We report the case of an 87-y-old woman with renal insufficiency who developed a surgical site infection with refractory methicillin-resistant Staphylococcus aureus. The standard dosage of linezolid (1200 mg daily) was not initially tolerated by the patient due to severe thrombocytopenia, but she was successfully treated when the dose was reduced by half (600 mg daily) based on a population pharmacokinetic-pharmacodynamic model. Appropriate dose adjustments can be made to optimize linezolid therapy especially in cases with preexisting renal dysfunction.

KW - Linezolid

KW - Renal insufficiency

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=84871370272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871370272&partnerID=8YFLogxK

U2 - 10.3109/00365548.2012.708783

DO - 10.3109/00365548.2012.708783

M3 - Article

C2 - 22992056

AN - SCOPUS:84871370272

SN - 2374-4235

VL - 45

SP - 77

EP - 80

JO - Infectious Diseases

JF - Infectious Diseases

IS - 1

ER -

A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this